1,757 results on '"Rammensee, Hans-Georg"'
Search Results
52. Supplementary Table 2 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
53. Supplementary Figure 2 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
54. Supplementary Table 6 from Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
55. Supplementary Tables 1-5, 7, 9-12 from Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
56. Supplementary Table 8 from Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
57. Data from Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
58. Supplementary Methods and Materials from Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas
59. Supplementary Figures 1-6 from Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
60. Supplementary Figure 1 from Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells
61. Data from Tumor-Associated MICA Is Shed by ADAM Proteases
62. Supplementary Movie from Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells
63. Supplementary Table 1 from A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays
64. Data from Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas
65. Data from A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays
66. Supplementary Figures 1-3 from Tumor-Associated MICA Is Shed by ADAM Proteases
67. Supplementary Figure Legend from Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas
68. Data from Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells
69. Supplementary Figure 1 from Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas
70. Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
71. From Basic Immunology to New Therapies for Cancer Patients
72. Identification of Vaccinia Virus Epitope-Specific HLA-A* 0201-Restricted T Cells and Comparative Analysis of Smallpox Vaccines
73. Graft versus self (GvS) against T-cell autoantigens is a mechanism of graft–host interaction
74. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
75. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
76. "Electronic Nose" Detects Major Histocompatibility Complex-Dependent Prerenal and Postrenal Odor Components
77. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
78. The Heat Shock Protein gp96: A Receptor-Targeted Cross-Priming Carrier and Activator of Dendritic Cells
79. Cleavage Motifs of the Yeast 20S Proteasome β Subunits Deduced from Digests of Enolase 1
80. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy
81. timsTOF mass spectrometry-based immunopeptidomics refines tumor antigen identification
82. Staining of activated ß2-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells
83. T cells of colorectal cancer patients’ stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells
84. IMMU-28. THE INTRA-TUMORAL SPATIAL HETEROGENEITY OF T CELL ANTIGENS IN GLIOBLASTOMA: AN INTEGRATED MULTI-OMICS APPROACH
85. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy
86. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
87. First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications
88. Simultaneous Identification of Functional Antigen-Specific CD8+ and CD4+ Cells after In Vitro Expansion Using Elongated Peptides
89. Disulfide-stabilized recombinant MHC class I molecules allow the generation of peptide-receptive MHC tetramers
90. Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade
91. IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
92. Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols
93. Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies
94. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade
95. 64 Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET
96. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)
97. Dipeptides catalyze rapid peptide exchange on MHC class I molecules
98. “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015
99. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during checkpoint blockade
100. Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.